A New Perspective on Drug Vial Optimization

Simple item page
dc.contributor.advisorGarey, Kevin W.
dc.contributor.committeeMemberVarkey, Divya A.
dc.contributor.committeeMemberReece, Kelley M.
dc.contributor.committeeMemberSpivey, Susan M.
dc.contributor.committeeMemberRoux, Ryan K.
dc.creatorAshemore, Arlin
dc.date.accessioned2020-06-09T02:43:59Z
dc.date.available2020-06-09T02:43:59Z
dc.date.createdMay 2020
dc.date.issued2020-05
dc.date.submittedMay 2020
dc.date.updated2020-06-09T02:43:59Z
dc.description.abstractPurpose: Historically, MD Anderson Cancer Center pharmacy areas utilized a strategic process referred to as, drug vial optimization (DVO) to extend the beyond-use date for single-use intravenous drug products. Under this strategy, partially used vials of drug were available for a greater period of time to satisfy medication orders prior to having to be discarded. This ultimately resulted in a reduction of drug waste and associated reduce drug cost. Recently updated USP chapter <797> guidelines has since halted the ability to utilize this strategy further. It became prudent to identify a new waste mitigation strategy. MD Anderson Cancer Center Outpatient Pharmacy began a focused effort of ordering the smallest vial size commercially available of rituximab to in an effort to minimize partial vial waste. This process is referred to as, drug vial size optimization (DVSO). Methods: A retrospective review of data related to rituximab administration and waste reports at MD Anderson outpatient-pharmacy between March 2019 and January of 2020 was conducted. Results: For MD Anderson outpatient pharmacy, it was discovered that the percent of waste of weekly rituximab use increased from near zero percent to 6.9% (p<0.001) per week following cessation of the DVO process. Following implementation of DVSO, the percent of waste of weekly rituximab reduced to 3.9% to a new weekly average of 3.0% (p<0.001).
dc.description.departmentPharmacy Practice and Translational Research, Department of
dc.format.digitalOriginborn digital
dc.format.mimetypeapplication/pdf
dc.identifier.urihttps://hdl.handle.net/10657/6743
dc.language.isoeng
dc.rightsThe author of this work is the copyright owner. UH Libraries and the Texas Digital Library have their permission to store and provide access to this work. Further transmission, reproduction, or presentation of this work is prohibited except with permission of the author(s).
dc.subjectRITUXIMAB
dc.subjectDRUG VIAL OPTIMIZATION
dc.subjectWASTE
dc.subjectPARTIAL VIAL WASTE
dc.subjectDRUG EXPENSE
dc.subjectCOST
dc.subjectDRUG VIAL SIZE OPTIMIZATION
dc.subjectAMAZON
dc.subjectDVO
dc.subjectDVSO
dc.subjectFDA
dc.subjectCMS
dc.subjectPHARMACY
dc.subjectMEDICINE
dc.subjectCLOSED SYSTEM TRANSFER DEVICE
dc.titleA New Perspective on Drug Vial Optimization
dc.type.dcmiText
dc.type.genreThesis
thesis.degree.collegeCollege of Pharmacy
thesis.degree.departmentPharmacy Practice and Translational Research, Department of
thesis.degree.disciplinePharmacy Leadership & Administration
thesis.degree.grantorUniversity of Houston
thesis.degree.levelMasters
thesis.degree.nameMaster of Science

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
ASHEMORE-THESIS-2020.pdf
Size:
791.42 KB
Format:
Adobe Portable Document Format
Download

License bundle

Now showing 1 - 2 of 2
No Thumbnail Available
Name:
PROQUEST_LICENSE.txt
Size:
4.43 KB
Format:
Plain Text
Description:
Download
No Thumbnail Available
Name:
LICENSE.txt
Size:
1.81 KB
Format:
Plain Text
Description:
Download

Collections

Published ETD Collection